Literature DB >> 27677759

[Therapeutic plasma exchange for the treatment of hypertriglyceridemia-induced pancreatitis : A case report].

G Eden1,2, F Gradaus3, K Brown4, I Gauert3, C Sass5, J T Kielstein4,6.   

Abstract

A rare but serious form of pancreatitis is caused by severe hypertriglyceridemia. It accounts for up to 10 % of all acute pancreatitis episodes. Despite a pathophysiology that differs distinctly from other forms of pancreatitis, there are no accepted guidelines for the treatment of hypertriglyceridemia-induced pancreatitis. We report a morbidly obese (BMI 45 kg/m²) 36-year-old Caucasian woman with a history of schizophrenic psychosis who was transferred to our tertiary care hospital for further diagnosis and treatment of increasing abdominal pain and hypertryglyceridemia of 2757 mg/dl. Due to rapid clinical deterioration, requiring invasive mechanical ventilation we performed therapeutic plasma exchange (TPE). About 1.5 times of the patient's calculated plasma volume was exchanged using fresh frozen plasma as substitution fluid. After a single TPE the triglyceride levels decreased by 86 % to 387 mg/dl. Concomitantly C‑reactive protein decreased from 303 to 179 mg/dl. Despite the paucity of data, TPE may be a beneficial means to lower triglycerides in patients with hypertriglyceridemia-induced pancreatitis, due to the rapid removal of the causative agent leading to pancreatic injury.

Entities:  

Keywords:  Anticoagulation; Apheresis; Extracorporeal treatment; Intensive care medicine

Mesh:

Year:  2016        PMID: 27677759     DOI: 10.1007/s00063-016-0219-z

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  8 in total

Review 1.  Issues in hyperlipidemic pancreatitis.

Authors:  Dhiraj Yadav; C S Pitchumoni
Journal:  J Clin Gastroenterol       Date:  2003-01       Impact factor: 3.062

2.  [Three shades of fluids: Bergström 2.0 / Furosemide stress test / replacement fluid for therapeutic plasma exchange].

Authors:  Julius J Schmidt; Jan T Kielstein
Journal:  Dtsch Med Wochenschr       Date:  2015-06-12       Impact factor: 0.628

3.  American Society for Apheresis guidelines on the use of apheresis in clinical practice: practical, concise, evidence-based recommendations for the apheresis practitioner.

Authors:  Jeffrey L Winters
Journal:  J Clin Apher       Date:  2014-05-30       Impact factor: 2.821

Review 4.  Pathogenesis, differentiation and management of hypertriglyceridemia.

Authors:  R J Havel
Journal:  Adv Intern Med       Date:  1969

5.  Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.

Authors:  Trung C Nguyen; Yong Y Han; Joseph E Kiss; Mark W Hall; Andrea Cortese Hassett; Ron Jaffe; Richard A Orr; Janine Janosky; Joseph A Carcillo
Journal:  Crit Care Med       Date:  2008-10       Impact factor: 7.598

Review 6.  Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy.

Authors:  Mitchell S Cappell
Journal:  Med Clin North Am       Date:  2008-07       Impact factor: 5.456

Review 7.  Antibiotic use in acute pancreatitis: Global overview of compliance with international guidelines.

Authors:  Minas Baltatzis; Santhalingam Jegatheeswaran; Derek A O'Reilly; Ajith K Siriwardena
Journal:  Pancreatology       Date:  2016-01-12       Impact factor: 3.996

8.  Assessment of Hemostasis after Plasma Exchange Using Rotational Thrombelastometry (ROTEM).

Authors:  Gerold Thölking; Rolf Mesters; Ralf Dittrich; Hermann Pavenstädt; Philipp Kümpers; Stefan Reuter
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

  8 in total
  1 in total

1.  Therapeutic plasma exchange in a tertiary care center: 185 patients undergoing 912 treatments - a one-year retrospective analysis.

Authors:  Julius J Schmidt; Firas Asper; Gunilla Einecke; Gabriele Eden; Carsten Hafer; Jan T Kielstein
Journal:  BMC Nephrol       Date:  2018-01-15       Impact factor: 2.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.